Lenire Tinnitus Treatment Device

09/03/2026

Neuromod is at the DoubleTree by Hilton in Orlando, FL for the 2026 Joint Defense Veterans Audiology Conference.

Visit Booth 11 at to speak with the team about , the first and only FDA-approved bimodal neuromodulation device for tinnitus.

Lenire is now a treatment option for the 3.2 million veterans living with tinnitus through the U.S. Department of Veterans Affairs.

Visit https://www.lenire.com/lenire-for-veterans/ to learn how Lenire can give Veterans relief from tinnitus.

19/02/2026

Read Mass Device's coverage of the second real patient analysis of U.S. tinnitus patients treated with . The paper, written by Dr. Craig Kasper of NYHD | Institute For Hearing & Balance, found that 81.8% of 140 patients treated with Lenire reported relief from tinnitus and had a mean reduction of 23.8 points on the THI scale.

Results reported in this paper, published in ASHA Journals, are consistent with the first analysis of real world U.S. tinnitus patient's treated with Lenire, which was published in Nature Portfolio.

Neuromod Devices today announced new data supporting the use of its Lenire tinnitus treatment device in U.S. patients.

06/02/2026

In this conversation with Patrick A. Lynch, Esq., MBA, CEO of the American Tinnitus Association, Dr. Ross O'Neill, Founder & CEO of Neuromod and Dr. Hubert Lim, Chief Scientific Officer of Neuromod Devices , answer the questions that matter most, drawing on clinical trial data and real-world evidence from Lenire providers.

Whether you’re living with tinnitus, considering as a treatment option, or a provider exploring whether to offer Lenire, this conversation offers clear, practical guidance grounded in evidence and experience.

Is Lenire right for you? Drs. Ross O'Neill (Founder & CEO, Neuromod Devices) and Hubert Lim (Chief Scientific Officer) answer the questions that matter most,...

04/02/2026

84.1% of 97 Americans with bothersome tinnitus reported significant relief after treatment with bimodal neuromodulation device, Lenire, a new study has found.

Findings in this paper demonstrate the effectiveness of Lenire and indicate a strong correlation between THI and TFI treatment outcome measures.

The study, written by Dr. Brian Fligor Ph. D. and Dr. Miles Sabine Au. D. of Tobias & Battite Hearing Wellness in Boston, M.A., is now available on bioRxiv & medRxiv.

This paper is the third in a series of ongoing, real-world evidence publications that have been compiled from thousands of American tinnitus patients that have been successfully treated with Lenire by independent clinicians.

These results are consistent with Lenire's first two real-world analyses of U.S. tinnitus patients treated with Lenire. These papers were published in Nature Portfolio and ASHA Journals (The American Journal of Audiology).

You can read a breakdown of the paper on Audiology Online.

Real-world analysis of 97 Americans with bothersome tinnitus who were treated with Lenire has been made available on medRxiv, a preprint server for health sciences.

03/02/2026

Neuromod Chief Operating Officer, Diarmuid Flavin will be speaking in The House of Lords tomorrow as part of UK Tinnitus Week Campaign.

Lenire by Neuromod has proudly supported Tinnitus UK's Tinnitus Week campaign for nearly a decade because we share the same vision for a world free of tinnitus.

Key to Tinnitus UK's vision is collaboration with the research community, and improving tinnitus patient's access to care and evidence-based treatment options.

In 2025, Lenire was honoured to receive the highest rating for effectiveness and safety from Tinnitus UK. This rating is owed to our commitment to building a compelling body of evidence for Lenire. As well as this, we partner with tinnitus care experts around the world to offer treatment with Lenire and continuously improve the overall quality of care for tinnitus patients.

Tinnitus UK and Neuromod's presence in The House of Lords is a testament to our long-term collaboration and we are excited for what the future holds.

03/02/2026

Watch Ben Thompson, AuD discuss how Treble Health and Neuromod's new partnership is with leading tinnitus care expert, Gail B Brenner,Au.D.. 🧠

This wide ranging discussion explores Dr. Brenner's history in tinnitus care, and how Lenire by Neuromod is helping her patients get clinically proven relief from tinnitus. 👂 🧘

Neuromod is excited to partner with Treble Health to expand the availability of Lenire in Philadelphia and Charlotte through the The Tinnitus Treatment Center of Philadelphia with Dr. Gail B Brenner,Au.D. and Audiology & Hearing Services of Charlotte with Dr. Melissa Karp Au. D.

➡️ Unlock Lasting Relief From Tinnitus! Schedule a FREE Consultation with Treble Health Today: https://treble.health/schedule254Dr. Ben interviews Dr. Gail B...

21/01/2026

Lenire by Neuromod is proud to sponsor Tinnitus UK's Tinnitus Week campaign from February 2 – 9, 2026.

Lenire was rated as the safest, most effective available tinnitus treatment option by Tinnitus UK in 2025. This rating is based on Neuromod's commitment to building clinical trial and real world evidence for Lenire.

For nearly a decade, Lenire has sponsored Tinnitus Week to support Tinnitus UK's ongoing mission of raising awareness, publishing insightful research, and supporting the 15% of adults living with constant noise.

Lenire by Neuromod and Tinnitus UK share a common mission of improving the standard of care for tinnitus patients and transforming the perception of tinnitus around world.

15/01/2026

Neuromod is excited to announce partnership with Treble Health to expand the availability of FDA Approved Lenire Tinnitus Treatment Device in Charlotte and Philadelphia via the Treble Health network.

Lenire will be available through Dr. Brenner Au.D. at The Tinnitus Treatment Center of Philadelphia, and Dr. Melissa Karp at the Audiology & Hearing Services of Charlotte.

“Expanding the awareness and availability of Lenire to tinnitus patients in the USA and globally is a priority for Neuromod.” said Eric Timm, President, Global Commercial Operations & CEO, Neuromod Devices USA Inc. “I’m delighted this partnership with Treble Health will give people living with tinnitus broader access to treatment with Lenire supported by guidance from expert clinicians.”

Treble Health founder, Dr. Ben Thompson Au. D. is a leading advocate in the field of tinnitus. His work has raised awareness of evidence based tinnitus treatment options for the 25 million Americans living with the condition.

Partnership with Treble Health will ensure that those living with tinnitus will have knowledge of, and access to, evidence-based tinnitus treatment options.

We're looking forward to our life-changing collaboration in 2026 and beyond.

14/01/2026

The American Journal of Audiology (ASHA Journals) has peer-reviewed and published the 2nd real world analysis of tinnitus patients treated with Lenire.

The analysis of 140 patients treated by Craig Kasper and his team at NYHD - New York Hearing Doctors found that 81.8% reported clinically significant relief from tinnitus treatment with Lenire by Neuromod.

"Lenire was nothing less than a game-changer in my life. I went from debilitating, almost catastrophic tinnitus, that required medication to treat the depression and anxiety, to being able to enjoy life again after four months of Lenire.” said Richard Bistrong, tinnitus patient at New York Hearing Doctors.

These results are consistent with the first analysis of U.S. tinnitus patients treated with tinnitus. This research, conducted by Emily E. McMahan, AuD at Alaska Hearing & Tinnitus Center, was published by Nature Portfolio.

Lenire now has the largest volume of clinical trial and real-world evidence for a tinnitus-specific treatment device. You can real the full release and find a link to the paper, as well as other resources, by clicking the link below.

https://www.lenire.com/lenire-real-world-evidence-american-journal-audiology/

Lenire Real World Evidence Positive Results Peer-Reviewed and Published in The American Journal of Audiology.

08/01/2026

We’re proud to partner with leading clinics across the U.S. and Europe, including Doc Side Audiology and Kelly Breese, Au.D. who are supporting patients with , the first and only tinnitus treatment device.

Discover how Lenire is helping people manage tinnitus every day at https://www.lenire.com/resources/patient-stories/

02/01/2026

“Super happy with the results.”

Feedback like this reflects the real-world experiences of people using as part of their tinnitus care journey, and we’re grateful to those who take the time to share.

Discover more Lenire patient stories on the Lenire blog, https://www.lenire.com/resources/blog/

31/12/2025

Happy New Year to our friends, colleagues, partners, and everyone living with tinnitus, from all of us at Neuromod Devices.

As we reflect on 2025, we’re deeply grateful for the trust, support, and meaningful connections we’ve built along the way. Here’s to a brighter future, continued collaboration, and making an even greater impact together in 2026.

Wishing you health, happiness, and hope in the year ahead.